Less than 56 days And you will have wished you sold at $4.
Thomvest greed has intentionally destroyed all potential here. They are in the process of shutting everything down, one by one, every quarter. They have stopped progressing the technology on many fronts. Nobody in their right mind would partner with these guys now. Do you think Consonance pulled the plug because they were going to make money, or because they realized that what was going on was unethical or nonprofitable for them. They already lost tens of millions!
The only thing Liminal is concerned about now is the several hundreds of plaintiffs who will expose what they have done. Knowing Thomvest history and plan will provide you perspective, and will foreshadow what's in store. Compensating 1B for what they stole and take private is still a deal for them. Pay for the shares that they stole, simple as that.
Take a look at these analysts, they have a 50% or less track record. Think that's good? The target only gets lower and will continue to do so. You'll be lucky to get anything out of this when all said and done! $4 will only become an unobtainable dream moving forward.
The only ones left are management, the pigs at the trough. They don't know what they are doing with all the lead scientists now gone. They have systematically pulled out all the pokers in the fire. Why? Well it's obviously for their gain somehow. Steal it out the back door so Thomvest can take private? Annihilate destructive technology for another entity? Deny children and families life saving technology, doubt it, but just the cost of doing business that they are willing to accept? Whatever the reason they put this into place years ago with Coulow.
Even the technology and patents that they systematically discontinue, wright down, or have, are not owned by Liminal. Even if FDA approved Riplazim they are so far away from producing it now! The team that could have pulled this off, they are gone! Batches haven't run for years. Thomvest internally and intentionally destroyed this company with their internal hostile takeover. These guys didn't play by the same rules that others need to respect.They will be exposed to the business world, this you can count on!
This excerpt is from the financials, expect more of this. Without giving anything away, such as Informing shareholders that there was a lawsuit in place, or that the patents are held by SALP, is only an attempt to cover themselves. They have created a web of lies to cover up their intent. The truth shall set you free!
See what is going on.,...
Impairment losses
2020
During the year ended December 31, 2020, we recorded impairments on our assets totalling $20.9 million mainly due to the impairments explained below.
At the end of 2020, in reviewing our portfolio of compounds in the small molecule therapeutics segment, we identified impairment indicators for certain patents. One of the patent families concerned a molecule that had entered a phase 1 clinical trial in 2019 that was subsequently discontinued after the review of the pharmacokinetic data for the first three cohorts obtained. Additional pre-clinical studies conducted in 2020 to further our understanding of the mechanism of action, or MOA, led to findings that the MOA included engaging a receptor which has been known in other products which engage the same receptor to occasionally cause undesirable side effects. Subsequently, we decided that the preclinical and clinical development activities associated with demonstrating that such molecule did not induce such side effects would be both time-consuming and costly and therefore the future development has been suspended. Another patent family impaired concerned another molecule that is licensed for development with a third party, whose research and development work we believe to be delayed from the agreed upon timelines and is unlikely to perform significant development in the near future. Further, the development of another compound was deprioritized as we wish to prioritize development of our lead compound fezagepras, as well as GPR84 and OXER1 drug candidates, which led to the impairment of the related patents. These small molecules patents were written down to their net recoverable amount of $nil, as both the fair value less costs of disposal, or FVLCD and the value in use were determined to be insignificant, resulting in an impairment of $1.2 million for the year ended December 31, 2020.